R&D pipeline progressing well
20/11/20 -"Better than expected performance of Tepezza and the upcoming launch of Amivantamab should bolster Genmab’s top line in the near term. Moreover, encouraging clinical data for pipeline assets, ..."
Pages
49
Language
English
Published on
20/11/20
You may also be interested by these reports :
03/12/20
Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of ...
02/12/20
Recently, there has been pertinent share price performance divergence between Novartis and Roche. While, for a long time, Novartis had the upper ...
27/11/20
After being range-bound for the most part of 2019, UCB (Add, Belgium) gained momentum in October 2019 when the company made an acquisition in the ...
26/11/20
Novartis unveiled promising performance targets at its 2020 CMD. Besides striving for healthy top-line growth – driven by diverse innovations, the ...